| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
IFITM2; IFITM3; hCBS (IC50 = 5.9 μM); hCSE (IC50 = 12.1 μM)
(±)-Dihydroactinidiolide targets multiple biological pathways. It is a potent inhibitor of acetylcholinesterase (AChE). It acts as an antioxidant by scavenging DPPH and nitric oxide radicals. It regulates gene expression and photoacclimation in plants. It also exhibits antibacterial and anticancer activities. |
|---|---|
| ln Vitro |
In vitro, dihydroactinidiolide shows potent AChE inhibitory activity with an IC50 of 34.03 nM, which is superior to some established AChE inhibitors. It has scavenging activities for DPPH and nitric oxide radicals. It also exhibits antibacterial and anticancer activities.
|
| ln Vivo |
In vivo, dihydroactinidiolide has shown neuroprotective effects and anticarcinogenic properties. However, it also has genotoxic effects. It is a potent plant growth inhibitor and a regulator of gene expression.
|
| Enzyme Assay |
Non-cellular assays for dihydroactinidiolide typically involve measuring its AChE inhibitory activity using the Ellman's method, where the compound is incubated with the enzyme and a substrate, and the reaction is monitored spectrophotometrically. Its antioxidant activity is assessed using DPPH or ABTS radical scavenging assays.
|
| Cell Assay |
Cellular assays for dihydroactinidiolide are conducted using cancer cell lines to assess its anticancer activity. Cells are treated with the compound, and cell viability, proliferation, and apoptosis markers are measured. Neuroprotective effects are evaluated in neuronal cell lines exposed to oxidative stress.
|
| Animal Protocol |
In vivo animal experiments for dihydroactinidiolide are conducted in models of cancer, neurodegeneration, or other diseases. The compound is administered orally or via injection, and its effects on disease progression, behavior, and biomarkers are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of dihydroactinidiolide are not well-characterized. As a small, lipophilic molecule, it is likely absorbed and distributed to various tissues. Its metabolism and excretion have not been extensively studied.
|
| Toxicity/Toxicokinetics |
Toxicological data for dihydroactinidiolide indicate that it has genotoxic effects. It should be handled with care. Its safety profile is not fully established, and it is primarily a research compound.
|
| References |
|
| Additional Infomation |
Dihydroactinidiolide is a benzofuran compound. It has been reported to be found in the tea plant (Camellia sinensis), kiwifruit (Actinidia polygama), and other organisms with available data. See also: Dihydroactinolone (note moved to).
(±)-Dihydroactinidiolide is a versatile natural product with a wide range of biological activities. It is a potent AChE inhibitor and a promising lead compound for the development of therapeutic agents for neurodegenerative diseases. It is also a valuable tool for studying plant physiology and gene regulation. |
| Molecular Formula |
C11H16O2
|
|---|---|
| Molecular Weight |
180.24
|
| Exact Mass |
180.115
|
| CAS # |
15356-74-8
|
| Related CAS # |
Dihydroactinidiolide; 17092-92-1
|
| PubChem CID |
27209
|
| Appearance |
White to off-white solid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
296.1±9.0 °C at 760 mmHg
|
| Melting Point |
42-43°
|
| Flash Point |
120.2±16.1 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.504
|
| LogP |
2.26
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
13
|
| Complexity |
289
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C([H])=C2C1(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C2(C([H])([H])[H])C([H])([H])[H])=O
|
| InChi Key |
IMKHDCBNRDRUEB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H16O2/c1-10(2)5-4-6-11(3)8(10)7-9(12)13-11/h7H,4-6H2,1-3H3
|
| Chemical Name |
4,4,7a-trimethyl-6,7-dihydro-5H-1-benzofuran-2-one
|
| Synonyms |
(±)-Dihydroactinidiolide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (554.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5482 mL | 27.7408 mL | 55.4816 mL | |
| 5 mM | 1.1096 mL | 5.5482 mL | 11.0963 mL | |
| 10 mM | 0.5548 mL | 2.7741 mL | 5.5482 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
